ZVRA Zevra Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Zevra Therapeutics Inc reported revenue of $39.7M (up 53.3% from a year earlier), net income of $8.75M and diluted EPS of $0.14; over the last four quarters revenue was $136M and net income $58.3M; for the fiscal year ended December 2025 revenue was $106M, up 350.9% on the year before.
ZVRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $106M, gross profit n/a, operating income −$62.9M, net income $83.2M (margin 78.2%), EPS $1.35
- Fiscal year ended Dec 2024: revenue $23.6M, gross profit n/a, operating income −$87.0M, net income −$106M (margin -446.9%), EPS −$2.28
- Fiscal year ended Dec 2023: revenue $27.5M, gross profit n/a, operating income −$49.6M, net income −$46.0M (margin -167.7%), EPS n/a
- Fiscal year ended Dec 2022: revenue $10.2M, gross profit n/a, operating income −$42.6M, net income −$26.8M (margin -263.5%), EPS n/a
- Fiscal year ended Dec 2021: revenue $28.7M, gross profit n/a, operating income $7.73M, net income −$8.56M (margin -29.9%), EPS −$2.11
ZVRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $39.7M (up 53.3% year over year), net income $8.75M, EPS $0.14
- Quarter ended Mar 31, 2026: revenue $36.2M (up 77.5% year over year), net income $37.9M, EPS $0.60
- Quarter ended Dec 31, 2025 (from the annual report): revenue $34.1M (up 183.4% year over year), net income $12.2M, EPS $0.21
- Quarter ended Sep 30, 2025: revenue $26.1M (up 605.4% year over year), net income −$544K, EPS −$0.01
- Quarter ended Jun 30, 2025: revenue $25.9M (up 481.7% year over year), net income $74.7M, EPS $1.21
- Quarter ended Mar 31, 2025: revenue $20.4M (up 495.6% year over year), net income −$3.10M, EPS −$0.06
- Quarter ended Dec 31, 2024 (from the annual report): revenue $12.0M (down 6.8% year over year), net income −$35.7M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $3.70M (up 27.6% year over year), net income −$33.2M, EPS −$0.69
- Quarter ended Jun 30, 2024: revenue $4.45M (down 47.5% year over year), net income −$19.9M, EPS −$0.48
- Quarter ended Mar 31, 2024: revenue $3.43M (up 7.8% year over year), net income −$16.6M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $12.9M (up 539.0% year over year), net income −$19.9M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $2.90M (up 0.7% year over year), net income −$10.4M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $8.47M (up 551.5% year over year), net income −$2.57M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $3.18M (down 19.9% year over year), net income −$13.2M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $2.02M (down 21.7% year over year), net income $5.75M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $2.87M (up 46.3% year over year), net income −$6.62M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $1.30M (down 89.2% year over year), net income −$24.0M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $3.97M (down 67.3% year over year), net income −$1.86M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $2.58M, net income −$2.70M, EPS $0.84
- Quarter ended Sep 30, 2021: revenue $1.97M, net income −$1.76M, EPS −$0.06
ZVRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.60M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$69.7M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$33.5M, share buybacks $3.45M
- Fiscal year ended Dec 2022: operating cash flow −$18.7M, share buybacks $4.72M
- Fiscal year ended Dec 2021: operating cash flow $10.4M, share buybacks $2.81M
ZVRA balance sheet
- Jun 30, 2026: cash $145M, total assets $303M, total liabilities $85.1M, shareholders' equity $218M, long-term debt $0
- Mar 31, 2026: cash $95.6M, total assets $279M, total liabilities $72.8M, shareholders' equity $206M, long-term debt $0
- Dec 31, 2025: cash $62.4M, total assets $285M, total liabilities $130M, shareholders' equity $155M, long-term debt $61.9M
- Sep 30, 2025: cash $54.4M, total assets $270M, total liabilities $137M, shareholders' equity $133M, long-term debt $61.3M
- Jun 30, 2025: cash $47.7M, total assets $256M, total liabilities $139M, shareholders' equity $117M, long-term debt $60.7M
- Mar 31, 2025: cash $37.3M, total assets $173M, total liabilities $132M, shareholders' equity $41.0M, long-term debt $60.1M
- Dec 31, 2024: cash $33.8M, total assets $178M, total liabilities $138M, shareholders' equity $39.7M, long-term debt $59.5M
- Sep 30, 2024: cash $54.0M, total assets $192M, total liabilities $122M, shareholders' equity $69.8M, long-term debt $58.9M
What is ZVRA's revenue?
Zevra Therapeutics Inc reported $136M of revenue over its last four quarters, through June 30, 2026.
Is ZVRA profitable?
Yes. Zevra Therapeutics Inc earned $58.3M over the last four quarters.
What is ZVRA's EPS?
Diluted earnings per share over the last four quarters were $0.94; $0.14 in the latest quarter.